Isofol Medical AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was SEK 6.26 million compared to SEK 32.51 million a year ago. Basic loss per share from continuing operations was SEK 0.04 compared to SEK 0.2 a year ago. Diluted loss per share from continuing operations was SEK 0.04 compared to SEK 0.2 a year ago.
For the nine months, sales was SEK 0.721 million compared to SEK 10.94 million a year ago. Revenue was SEK 0.745 million compared to SEK 10.94 million a year ago. Net loss was SEK 28.16 million compared to SEK 134.42 million a year ago. Basic loss per share from continuing operations was SEK 0.17 compared to SEK 0.83 a year ago. Diluted loss per share from continuing operations was SEK 0.17 compared to SEK 0.83 a year ago.